Success Metrics

Active Trials
3(100%)

Phase Distribution

Ph phase_3
1
33%
Ph phase_4
2
67%

Phase Distribution

0

Early Stage

0

Mid Stage

3

Late Stage

Phase Distribution3 total trials
Phase 3Large-scale testing
1(33.3%)
Phase 4Post-market surveillance
2(66.7%)

Highest Phase Reached

Phase 4

Trial Status & Enrollment

Completion Rate

0.0%

0 of 0 finished

Non-Completion Rate

0.0%

0 ended early

Currently Active

3

trials recruiting

Total Trials

3

all time

Status Distribution
Active(3)

Detailed Status

Recruiting2
Active, not recruiting1

Development Timeline

Analytics

Development Status

Total Trials
3
Active
3
Success Rate
N/A
Most Advanced
Phase 4

Trials by Phase

Phase 31 (33.3%)
Phase 42 (66.7%)

Trials by Status

recruiting267%
active_not_recruiting133%

Recent Activity

3 active trials
Showing 3 of 3
active_not_recruitingphase_3

A Study of Inclisiran to Prevent Cardiovascular Events in High-risk Primary Prevention Patients.

NCT05739383
recruitingphase_4

Inclisiran Versus Placebo for the Prevention of Major Adverse Cardiovascular and Limb Events in Patients Undergoing Percutaneous Coronary Intervention or Peripheral Endovascular Intervention

NCT06909565
recruitingphase_4

LDL-C Optimization Using Inclisiran in Patients in Which Drug-Drug Interactions Limit LDL Lowering

NCT06865885

Clinical Trials (3)

Showing 3 of 3 trials
NCT05739383Phase 3

A Study of Inclisiran to Prevent Cardiovascular Events in High-risk Primary Prevention Patients.

Active Not Recruiting
NCT06909565Phase 4

Inclisiran Versus Placebo for the Prevention of Major Adverse Cardiovascular and Limb Events in Patients Undergoing Percutaneous Coronary Intervention or Peripheral Endovascular Intervention

Recruiting
NCT06865885Phase 4

LDL-C Optimization Using Inclisiran in Patients in Which Drug-Drug Interactions Limit LDL Lowering

Recruiting

All 3 trials loaded

Drug Details

Intervention Type
DRUG
Total Trials
3